Cargando…

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

BACKGROUND: NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. METHODS: We initiated a randomized, placebo-controlled, phase 1–2 trial to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keech, Cheryl, Albert, Gary, Cho, Iksung, Robertson, Andreana, Reed, Patricia, Neal, Susan, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Haixia, Smith, Gale, Patel, Nita, Frieman, Matthew B., Haupt, Robert E., Logue, James, McGrath, Marisa, Weston, Stuart, Piedra, Pedro A., Desai, Chinar, Callahan, Kathleen, Lewis, Maggie, Price-Abbott, Patricia, Formica, Neil, Shinde, Vivek, Fries, Louis, Lickliter, Jason D., Griffin, Paul, Wilkinson, Bethanie, Glenn, Gregory M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494251/ https://www.ncbi.nlm.nih.gov/pubmed/32877576 http://dx.doi.org/10.1056/NEJMoa2026920

Ejemplares similares

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
por: Mallory, Raburn M, et al.
Publicado: (2022)

2753. Induction of Broadly Cross-Reactive Immune Responses Against A(H3N2) Airuses: Results of a Phase 2 Trial of a Novel Recombinant Hemagglutinin Saponin-Adjuvanted Nanoparticle Seasonal Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2019)

LB19. Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants
por: Fries, Louis, et al.
Publicado: (2018)

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
por: Shinde, Vivek, et al.
Publicado: (2020)

Strong CD4(+) T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination
por: Fries, Louis, et al.
Publicado: (2023)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
por: Formica, Neil, et al.
Publicado: (2021)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses
por: Rydyznski Moderbacher, Carolyn, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
por: Plested, Joyce S., et al.
Publicado: (2023)

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
por: Logue, James, et al.
Publicado: (2023)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
por: Tian, Jing-Hui, et al.
Publicado: (2021)

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
por: Weston, Stuart, et al.
Publicado: (2020)

Coronavirus interactions with the cellular autophagy machinery
por: Miller, Katelyn, et al.
Publicado: (2020)

A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection
por: Zhu, Mingzhu, et al.
Publicado: (2023)

Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
por: Áñez, Germán, et al.
Publicado: (2023)

PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
por: Logue, James, et al.
Publicado: (2022)

SIRT-1 is required for release of enveloped enteroviruses
por: Jassey, Alagie, et al.
Publicado: (2023)

2637. Third Trimester Immunization with an Respiratory Syncytial Virus F Protein Vaccine for the Prevention of RSV Lower Respiratory Tract Infection in Infants
por: Fries, Louis F, et al.
Publicado: (2019)

A Yeast Suppressor Screen Used To Identify Mammalian SIRT1 as a Proviral Factor for Middle East Respiratory Syndrome Coronavirus Replication
por: Weston, Stuart, et al.
Publicado: (2019)

COVID-19: Knowns, Unknowns, and Questions
por: Weston, Stuart, et al.
Publicado: (2020)

Respiratory Viruses
por: Weston, Stuart, et al.
Publicado: (2019)

Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA
por: Portnoff, Alyse D., et al.
Publicado: (2020)

2’,3’ cyclic-nucleotide 3’-phosphodiesterase (CNP) inhibits SARS-CoV-2 virion assembly by blocking infection-induced mitochondria depolarization
por: Logue, James, et al.
Publicado: (2023)

Abstract: Paper presentation: Socio-demographic profile of patients with Pulmonary Tuberculosis associated with psychiatric co-morbidities.
por: Chinar, Chinar, et al.
Publicado: (2022)

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
por: Fries, Louis, et al.
Publicado: (2017)

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
por: Guebre-Xabier, Mimi, et al.
Publicado: (2020)

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
por: Madhi, Shabir A, et al.
Publicado: (2022)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

Genome-enabled discovery of evolutionary divergence in brains and behavior
por: Patil, Chinar, et al.
Publicado: (2021)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination
por: Alter, Galit, et al.
Publicado: (2021)

Opinion: Advancing Embodiment Research From a Developmental Point of View
por: Lickliter, Robert
Publicado: (2021)

Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus
por: Lewnard, Joseph A., et al.
Publicado: (2022)

Host Cell Glycocalyx Remodeling Reveals SARS-CoV-2 Spike Protein Glycomic Binding Sites
por: Sheng, Ying, et al.
Publicado: (2022)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
por: Toback, Seth, et al.
Publicado: (2022)

Behavior-dependent cis regulation reveals genes and pathways associated with bower building in cichlid fishes
por: York, Ryan A., et al.
Publicado: (2018)

The Unfolded Protein Response in Breast Cancer
por: McGrath, Eoghan P., et al.
Publicado: (2018)

Paroxysmal Hemicrania
por: Osman, Chinar, et al.
Publicado: (2018)

Barriers and enablers to screening and diagnosing depression and diabetes distress in people with type 2 diabetes mellitus; protocol of a qualitative evidence synthesis
por: McGrath, Niamh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4ik5clk0nb8fvinb3j44kal6s